273 related articles for article (PubMed ID: 22951237)
1. The role of monoamine oxidase inhibitors in depression treatment guidelines.
Thase ME
J Clin Psychiatry; 2012; 73 Suppl 1():10-6. PubMed ID: 22951237
[TBL] [Abstract][Full Text] [Related]
2. MAOIs and depression treatment guidelines.
Thase ME
J Clin Psychiatry; 2012 Jul; 73(7):e24. PubMed ID: 22901357
[TBL] [Abstract][Full Text] [Related]
3. The use of monoamine oxidase inhibitors in primary care.
Culpepper L
J Clin Psychiatry; 2012; 73 Suppl 1():37-41. PubMed ID: 22951241
[TBL] [Abstract][Full Text] [Related]
4. The transdermal delivery system of monoamine oxidase inhibitors.
VanDenBerg CM
J Clin Psychiatry; 2012; 73 Suppl 1():25-30. PubMed ID: 22951239
[TBL] [Abstract][Full Text] [Related]
5. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
Flockhart DA
J Clin Psychiatry; 2012; 73 Suppl 1():17-24. PubMed ID: 22951238
[TBL] [Abstract][Full Text] [Related]
6. MAOIs: issues in treatment adherence and rates of treatment failure.
Cohen LJ; Sclar DA
J Clin Psychiatry; 2013 Jan; 74(1):e02. PubMed ID: 23419230
[TBL] [Abstract][Full Text] [Related]
7. MAOIs and transdermal delivery.
Vandenberg CM
J Clin Psychiatry; 2012 Sep; 73(9):e28. PubMed ID: 23059160
[TBL] [Abstract][Full Text] [Related]
8. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Tobin M
Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
[No Abstract] [Full Text] [Related]
9. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
10. Discussion: a fresh look at monoamine oxidase inhibitors for depression.
Cohen LJ; Sclar DA; Culpepper L; Flockhart DA; Hirschfeld RM; Thase ME; VanDenBerg CM
J Clin Psychiatry; 2012; 73 Suppl 1():42-5. PubMed ID: 22951242
[No Abstract] [Full Text] [Related]
11. Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.
Kennedy SH
J Psychiatry Neurosci; 1997 Mar; 22(2):127-31. PubMed ID: 9074307
[TBL] [Abstract][Full Text] [Related]
12. Revisiting monoamine oxidase inhibitors.
Krishnan KR
J Clin Psychiatry; 2007; 68 Suppl 8():35-41. PubMed ID: 17640156
[TBL] [Abstract][Full Text] [Related]
13. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.
Shulman KI; Fischer HD; Herrmann N; Huo CY; Anderson GM; Rochon PA
J Clin Psychiatry; 2009 Dec; 70(12):1681-6. PubMed ID: 19852903
[TBL] [Abstract][Full Text] [Related]
14. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art.
Rapaport MH
J Clin Psychiatry; 2007; 68 Suppl 8():42-6. PubMed ID: 17640157
[TBL] [Abstract][Full Text] [Related]
15. The use of MAOIs in primary care.
Culpepper L
J Clin Psychiatry; 2012 May; 73(5):e19. PubMed ID: 22697202
[TBL] [Abstract][Full Text] [Related]
16. Current place of monoamine oxidase inhibitors in the treatment of depression.
Shulman KI; Herrmann N; Walker SE
CNS Drugs; 2013 Oct; 27(10):789-97. PubMed ID: 23934742
[TBL] [Abstract][Full Text] [Related]
17. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
[TBL] [Abstract][Full Text] [Related]
18. Issues in adherence to treatment with monoamine oxidase inhibitors and the rate of treatment failure.
Cohen LJ; Sclar DA
J Clin Psychiatry; 2012; 73 Suppl 1():31-6. PubMed ID: 22951240
[TBL] [Abstract][Full Text] [Related]
19. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Bodkin JA; Amsterdam JD
Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
